What is Think Bioscience?
Think Bioscience is a privately held small molecule drug discovery company based in Boulder, Colorado. The company distinguishes itself by targeting proteins and pathways that have been considered "undruggable" using conventional methods. Its multidisciplinary team leverages expertise across synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry. This integrated approach aims to create first-in-class programs for diseases that currently lack effective treatment options, positioning Think Bioscience at the forefront of challenging therapeutic areas.
How much funding has Think Bioscience raised?
Think Bioscience has raised a total of $73.9M across 3 funding rounds:
Angel/Pre-Seed
$1.9M
Seed
$17M
Series A
$55M
Angel/Pre-Seed (2021): $1.9M, investors not publicly disclosed
Seed (2022): $17M led by Xora Innovation, Innovation Endeavors, and AV8 Ventures
Series A (2026): $55M supported by Innovation Endeavors, Regeneron Ventures, Janus Henderson Investors, Crescent Enterprises, MBX Capital, Colorado Venture Partners, and AV8 Ventures
Key Investors in Think Bioscience
Xora Innovation
Xora Innovation is a venture capital firm that provides capital and support to deep tech entrepreneurs, focusing on transforming essential industries like compute communications, climate energy, and AI in physical industries. They partner with innovative companies addressing global demands through AI.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm investing in visionary founders and transformational technologies, particularly those leveraging data, computation, and advanced engineering across various sectors including life sciences.
AV8 Ventures
AV8 Ventures is an investment firm that supports early-stage startups in healthcare, enterprise, financial services, and deep-tech, aiming to empower founders in building category-defining companies through long-term partnerships.
What's next for Think Bioscience?
The recent major strategic investment signals a pivotal growth phase for Think Bioscience. This capital infusion is expected to accelerate the company's drug discovery and development pipeline, potentially enabling the advancement of its lead programs into preclinical and clinical stages. The company's focus on "undruggable" targets suggests a long-term strategy aimed at creating truly novel therapies, which could command significant market share if successful. Future funding rounds will likely depend on achieving key development milestones and demonstrating the efficacy and safety of its therapeutic candidates.
See full Think Bioscience company page
